Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarucizumab Reversal of Dabigatran in Emergency Situations (China Phase III)
CTR20171130Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of idarucizumab in need for urgent surgery, anticoagulant reversal, sponsored by Boehringer Ingelheim. Started Oct 2017; status: completed.
02
Drugs
idarucizumab
03
Conditions
need for urgent surgeryanticoagulant reversal
Beyond the preview
Go deeper on CTR20171130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171130.